Skip to main content

Rebyota®

Rebyota®(fecal microbiota, live – jslm):

Rebyota® is a proprietary, first-in-class, single-dose microbiota-based therapy indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection.

For additional information, please visit www.rebyota.com or for U.S. prescribing information, click here.

Rebyota logo

Important Safety Information

  • You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
  • You should report to your doctor any infection you think you may have acquired after administration.
  • REBYOTA may contain food allergens.
  • Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
  • REBYOTA has not been studied in patients below 18 years of age.
  • Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

To report SUSPECTED ADVERSE REACTIONS, contact RedHill Biopharma INC. at 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click to see the full Prescribing Information.